Jim Hayman

James Hayman, MD, MBA

Director of Clinical Division
Co-Director of the Michigan Radiation Oncology Quality Consortium (MROQC)

University Hospital
1500 E Medical Center Drive, UHB2C490
Ann Arbor, MI 48109-5010


Clinical Contacts

Phone: 734-936-4300

Administrative Contact

Michaela Saputo 734-764-4754


Dr. James Hayman came to the Department of Radiation Oncology following his Residency in 1996. He is a Professor and the Director of the Clinical Division and a 2014 ASTRO Fellow. Dr. Hayman's clinical research interests include the management of lung, esophageal, breast, skin, ocular and central nervous system malignancies. He is active in health services research, serves as a Co-Director of the Michigan Radiation Oncology Quality Consortium (MROQC), and is a national leader of quality improvement efforts in Radiation Oncology.

Areas of Interest

Health service research

  • Cost
  • Cost-effectiveness
  • Quality of care

Clinical Interests

  • Lung cancer
  • Esophageal cancer
  • Breast cancer
  • Skin cancer
  • Ocular malignancies
  • Central nervous system malignancies

Honors & Awards

2014 Fellow, American Society for Therapeutic Radiation Oncology (FASTRO)


  • MD, University of Chicago Pritzker School of Medicine, 1991
  • MBA, University of Chicago Graduate School of Business, 1991
  • Radiation Oncology Residency, Joint Center for Radiation Therapy at Harvard Medical School 1996
  • Board certifications:  Radiation Oncology, Hospice & Palliative Medicine


  • (PI:Pierce), 2/1/11 – 1/31/18, Michigan Blue Cross Blue Shield: The Michigan Radiation Oncology Quality Consortium, Role: Co-Director.
  • P01 CA059827-16-1 PI: Lawrence/TenHaken), National Institutes of Health/National Cancer Institute: Optimization of High Dose Conformal Therapy, Project 2:  Response-Driven Treatment of Non-Small Cell Lung Cancer, Role: Co-Investigator. 

Published Articles or Reviews

Selected from 64 publications

  • Shumway DA, Griffith KA, Pierce LJ, Feng M, Moran JM, Stenmark MH, Jagsi R, Hayman JA. Wide variation in the diffusion of a new technology: Practice-based trends in intensity-modulated radiation therapy (IMRT) use in the state of Michigan, with implications for IMRT use nationally. J Oncol Pract. 11:e373-9, 2015.
  • Jagsi R, Griffith KA, Boike TP, Walker E, Nurushev T, Grills IS, Moran JM, Feng M, Hayman J, Pierce LJ. Differences in the acute toxic effects of breast radiotherapy by fractionation schedule: Comparative analysis of physician-assessed and patient-reported outcomes in a large multicenter cohort. JAMA Oncol. 1:918-30, 2015.
  • Matuszak MM, Hadley SW, Feng M, Hayman JA, Brock KK, Burger P, Owen D, Suresh K, Schipper M, Lawrence TS, Moran JM. Enhancing safety and quality through pre-planning peer review for patients undergoing stereotactic body radiation therapy. Pract Radiat Oncol. 6:e39-46, 2016.
  • Valle LF, Jagsi R, Bobiak SN, Zornosa C, D'Amico TA, Pisters KM, Dexter EU, Niland JC, Hayman JA, Kapadia NS. Variation in definitive therapy for localized non-small cell lung cancer among national comprehensive cancer network institutions. Int J Radiat Oncol Biol Phys. 94:360-7, 2016.
  • Frohm ML, Griffith KA, Harms KL, Hayman JA, Fullen DR, Nelson CC, Wong SL, Schwartz JL, Bichakjian CK. Recurrence and survival in patients with Merkel Cell Carcinoma undergoing surgery without adjuvant radiation therapy to the primary site. JAMA Dermatol. Published online 6/1/2016.

Web Sites


1500 E Medical Center Dr
Ann Arbor, MI 48109-5010